|1.||Gentile, I: 1 article (12/2004)|
|2.||d'Errico, T: 1 article (12/2004)|
|3.||Montone, L: 1 article (12/2004)|
|4.||Visconti, M: 1 article (12/2004)|
|5.||Varriale, M: 1 article (12/2004)|
|6.||Borgia, G: 1 article (12/2004)|
|7.||Rossiello, R: 1 article (12/2004)|
|8.||Reynaud, L: 1 article (12/2004)|
|9.||Salvio, A: 1 article (12/2004)|
|10.||Borgia, F: 1 article (12/2004)|
|1.||Duodenal Ulcer (Curling's Ulcer)
09/01/1995 - "5. The data demonstrate that duodenal ulcer therapy with ebrotidine leads to a marked improvement in the protective qualities of gastric mucus essential for the maintenance of mucosal integrity and enhances the inherent mucosal defense against H. "
04/01/1997 - "Results showed that a daily dose of 400 mg ebrotidine is effective and safe in the treatment of duodenal ulcers."
04/01/1997 - "This Phase II study has been undertaken to establish the efficacy and safety of ebrotidine, administered in four dosages as a single evening dose versus placebo in the treatment of duodenal ulcer. "
04/01/1997 - "Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. "
09/01/1995 - "1. Gastric mucus from duodenal ulcer patients before and following therapy with a new antiulcer agent, ebrotidine, at 400, 600 and 800 mg dose was examined for changes in the physicochemical qualities and anti-H. "
04/01/1997 - "The histopathological study revealed significant reduction in the number of deep and superficial ulcers in ebrotidine-treated animals. "
04/01/1997 - "Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers."
07/01/1997 - "Ebrotidine--a nostrum for ulcer."
04/01/1997 - "The three groups treated with higher dosages (400 to 800 mg of ebrotidine daily) showed an endoscopic ulcer healing rate of 90-95%, significantly higher than 55% achieved with placebo (p < 0.05), whilst the differences between these three dosages of ebrotidine were not statistically significant. "
04/01/1997 - "pylori eradication, and the successful ulcer therapy with ebrotidine induces a significant (4-fold) increase in the H. "
|3.||Stomach Ulcer (Gastric Ulcer)
04/01/1997 - "Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer."
09/01/1997 - "Cell cycle progression during gastric ulcer healing by ebrotidine and sucralfate."
01/01/1992 - "When administered twice daily at various doses (1-100 mg/kg) for 10 days, ebrotidine reduced dose dependently the area of chronic gastric ulcers, and it was accompanied by significantly higher contents of epidermal growth factor (EGF) in the ulcer bed than in the intact mucosa. "
09/01/1997 - "2. Rats with experimentally induced gastric ulcers were treated twice daily for 14 days with either ebrotidine at 100 mg/kg, sucralfate at 100 mg/kg or vehicle, and at different stages of treatment their stomachs were used for quantitization of gastric mucosal PCNA and Cdk2 expression. "
05/01/1994 - "2. Rats with acetic acid-induced chronic gastric ulcers were treated twice daily for 14 consecutive days either with ebrotidine at 100 mg/kg or placebo, and then at different stages of treatment used for the isolation and quantitation of gastric mucosal laminin receptor. "
|4.||Peptic Ulcer (Peptic Ulcers)
04/01/1997 - "These results suggest that ebrotidine may be more useful than the classically known H2-antagonists in the treatment of peptic ulcers."
04/01/1997 - "This is a phase III, randomized, double-blind, clinical trial with two parallel groups of 50 patients to assess the efficacy of ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]ethyl ] amino]methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) 800 mg and ranitidine 300 mg as a single evening dose in the treatment of benign gastric peptic ulcer. "
08/01/1998 - "1. Gastric mucus from Helicobacter pylori-positive patients with active chronic gastritis type B, before and after successful combination therapy consisting of the H2 receptor antagonist ebrotidine (400 mg) and amoxicillin (1,000 mg) administered b.i.d., in the morning and at bedtime for a period of 2 weeks followed by administration of ebrotidine alone for the subsequent 4 weeks, was assessed for the changes in physicochemical properties associated with the mucosal protective potential and anti-H. "
08/01/1998 - "pylori associated with the successful therapy for active chronic gastritis type B with ebrotidine-amoxicillin was accompanied by a 36% increase in gastric mucus hydrogen ion retardation capacity, a 1.5-2.1-fold increase in mucus gel viscosity and a 2.4-fold increase in its hydrophobicity. "
09/01/1999 - "pylori lipopolysaccharide-induced acute gastritis to assess the effect of antiulcer agent, ebrotidine, on the gastric mucosal inflammatory responses by analyzing the interplay between the activity of a key apoptotic caspase, caspase-3, epithelial cell apoptosis, and the expression of inducible nitric oxide synthase (NOS-2). "
|8.||Epidermal Growth Factor (EGF)
|9.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|10.||Phosphoric Monoester Hydrolases (Phosphatases)